Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old

Millie Garg; Steven T Leach; Tamara Pang; Bronwen Needham; Michael J Coffey; Tamarah Katz; Roxanne Strachan; John Widger; Penelope Field; Yvonne Belessis; Sandra Chuang; Andrew S Day; Adam Jaffe; Chee Y Ooi

doi:10.1016/j.jcf.2017.07.011

Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old

J Cyst Fibros. 2018 Jan;17(1):109-113. doi: 10.1016/j.jcf.2017.07.011. Epub 2017 Jul 25.

Authors

Affiliations

¹ School of Women and Children's Health, Medicine, The University of New South Wales, High Street, Sydney Children's Hospital, Randwick 2031, New South Wales, Australia.
² Sydney Medical Program, The University of Sydney, Camperdown 2050, New South Wales, Australia.
³ Department of Nutrition and Dietetics, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia.
⁴ Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia.
⁵ School of Women and Children's Health, Medicine, The University of New South Wales, High Street, Sydney Children's Hospital, Randwick 2031, New South Wales, Australia; Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia.
⁶ Department of Paediatrics, University of Otago, Riccarton Ave, Christchurch 8011, Canterbury, New Zealand.
⁷ School of Women and Children's Health, Medicine, The University of New South Wales, High Street, Sydney Children's Hospital, Randwick 2031, New South Wales, Australia; Department of Gastroenterology, Sydney Children's Hospital, High Street, Randwick 2031, New South Wales, Australia. Electronic address: [email protected].

PMID: 28754328
DOI: 10.1016/j.jcf.2017.07.011

Abstract

Background: The pathogenesis of gut inflammation, bacterial dysbiosis and increased rates of malignancy in CF is unclear. Fecal M2-pyruvate kinase (M2-PK) is a biomarker indicative of cellular proliferation that may be raised in intestinal malignancy and inflammation. Biomarkers, including M2-PK, may be useful in assessing effects of novel therapies on the gastrointestinal tract.

Methods: M2-PK was measured in stools collected from patients with CF and HC (0-10years). Linear mixed model analysis was used.

Results: M2-PK levels did not significantly change in children with CF (36 patients, 77 samples) (P=0.998) or HC (45 patients, 45 samples) (P=0.21), over the age range 0-10years. Patients with CF had elevated M2-PK compared to HC (median [IQR; range]: 10.7 [5.7-28.6; 1.0-239.1] (n=77) vs. 1.0 [1.0-1.0; 1.0-50.0] (n=45) U/mL, respectively; P=0.001).

Conclusions: Fecal M2-PK was elevated in children with CF compared with HC during infancy and throughout childhood suggesting abnormalities in the CF gut exist in early life.

Keywords: Biomarkers; Cystic fibrosis; Gastrointestinal inflammation; Intestinal neoplasms; Pediatrics; Pyruvate kinase.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Australia / epidemiology
Biomarkers / analysis
Biomarkers / metabolism
Cell Proliferation / physiology
Child
Child, Preschool
Cystic Fibrosis* / diagnosis
Cystic Fibrosis* / epidemiology
Cystic Fibrosis* / metabolism
Cystic Fibrosis* / physiopathology
Feces / enzymology*
Female
Gastrointestinal Diseases* / diagnosis
Gastrointestinal Diseases* / epidemiology
Gastrointestinal Tract* / metabolism
Gastrointestinal Tract* / physiopathology
Humans
Infant
Infant, Newborn
Male
Prognosis
Pyruvate Kinase* / analysis
Pyruvate Kinase* / metabolism
Risk Factors

Substances

Biomarkers
Pyruvate Kinase